Menu

T-Cell

T-Cell
T-Cell Lymphoma Prognosis

In general, a diagnosis of T-cell lymphoma denotes a poorer

T-Cell
What is T-Cell Lymphoblastic Lymphoma?

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of

T-Cell
SMILE Regimen Effective Against Rare T-cell Subtype

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is

T-Cell
B-cell Lymphoma vs. T-cell Lymphoma: What Are The Differences Between The Two?

In non-Hodgkin's lymphoma, you have your B-cell lymphomas

T-Cell
Lymphomatoid Papulosis: Diagnosis and Treatment

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin

T-Cell
T Cell Lymphoma: Causes, Classification, and Diagnosis

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response,

T-Cell
Diagnosis and Staging of Cutaneous T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome

Cutaneous T-Cell Lymphoma (CTCL) is a rare, low grade (

T-Cell
Prognostic Indicators Involved In NK T Cell Lymphoma

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the

T-Cell
T-Cell Lymphoma? No Way, Not My Son! Part II

This article was written exclusively for LymphomaInfo.net by Linda Mitchelson, MitchDJ on

T-Cell
New Treatment for Cutaneous T-Cell Lymphoma Fast-Tracked

According to biopharmaceutical company Soligenix, the US Food and Drug Administration

T-Cell
T-Cell Lymphoma? No Way, Not My Son! Part I

This article was written exclusively for LymphomaInfo.net by Linda Mitchelson, MitchDJ on

T-Cell
FDA Approves Belinostat for Peripheral T-Cell Lmphoma

The US Food and Drug Administration's approval comes by way of the agency's accelerated

T-Cell
Seattle Genetics has interim data for Adcetris in cutaneous T-cell lymphoma

Seattle Genetics is announcing interim results from an investigator-sponsored phase II clinical

T-Cell
MD Anderson In Line for Big Payment to License CAR T Cell Therapy

MD Anderson Cancer Center is in line to receive $100 million in publicly traded stock as

T-Cell
Potential T-cell Lymphoma Treatment Withdrawn During Phase III Testing

Following an interim look at data from an ongoing phase III trial, Takeda Oncology has

Click for More Articles...